Ricerca Biosciences appoints drug safety director

Douglas Fuhrer has right skills to guide preclinical drug development strategy

Ricerca Biosciences, a US-based preclinical development contract research organisation (CRO) has appointed Douglas Fuhrer as senior director of drug safety.

Fuhrer has more than 12 years of experience directing teams of scientists and technicians in large pharmaceutical companies, biotech organisations and CROs. His training and experience includes applied animal investigation skills, serving as a study director of toxicology and safety pharmacology Good Laboratory Practice (GLP) studies and completing multiple INDs and non-clinical programmes supporting clinical development. His expertise lies within many therapeutic areas including anti-infectives, cancer, immune regulation, diabetes, CNS, prostate enlargement and hepatitis C.

‘Doug possesses the experience and insights necessary to guide our preclinical drug development strategies,’ said Michael Placke, senior vice president and general manager of Ricerca’s Concord, Ohio, drug development operations.

You may also like

Research & Development

Celerion and Ricerca Biosciences to provide integrated service for biosimilars

Will test viability of a potential biosimilar early in the process
Research & Development

Ricerca announces similarity analysis service

Foresight allows compound assay results to be compared against pharmacologically active compounds
Research & Development

Ricerca and LSP agree business development collaboration

Ricerca will expand its presence in Japan, Korea and overall Asian market
Regulatory

Ricerca completes purchase of MDS Pharma businesses

The acquisition gives Ohio-based Ricerca more capacity and capabilities.
Research & Development

MDS to sell early stage business to Ricerca

MDS Pharma Services is to sell its remaining discovery and pre-clinical operations to Ohio-based Ricerca Biosciences for US$45m.
Research & Development

Cirena and Epigenica launch technologies to accelerate genome editing and epigenomic research

Two life sciences companies have announced new technologies designed to address long-standing bottlenecks in genome editing and epigenomic analysis, offering faster timelines and improved reproducibility for researchers in academia and industry
Research & Development

PSI launches platform to speed up site ID, startup and enrolment in pivotal studies

SYNETIC is designed to speed up site identification, startup and patient enrollment in pivotal clinical trials
Subscribe now